Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative ...

Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update ...

We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors. Cancer immunotherapies targeting immune checkpoint molecules have revolutionized treatment across various cancer ...

Bavencio, a human anti-PD-L1 antibody, the first approved therapy for mMCC, was approved under accelerated approval based on tumour response and duration of response data. mMCC is a rare and ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...